Stock data
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) reported revenue of US$12.00B and net income of US$3.95B for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$12.00B | — | US$4.17B | US$3.95B | — |
| 2024 | US$11.02B | — | -US$232.90M | -US$535.60M | — |
| 2023 | US$9.87B | — | US$3.83B | US$3.62B | — |
| 2022 | US$8.93B | — | US$4.31B | US$3.32B | — |
| 2021 | US$7.57B | — | US$2.78B | US$2.34B | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$3.33B | US$1.10B | — |
| 2026-03-31 | US$2.99B | US$1.03B | — |
| 2025-12-31 | US$3.19B | US$1.19B | — |
| 2025-09-30 | US$3.08B | US$1.08B | — |
| 2025-06-30 | US$2.96B | US$1.03B | — |
| 2025-03-31 | US$2.77B | US$646.30M | — |
| 2024-12-31 | US$2.91B | US$913.00M | — |
| 2024-09-30 | US$2.77B | US$1.05B | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.